In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $205.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sean Laaman has given his Buy rating due to a combination of factors, primarily driven by the promising results from the HERIZON-GEA-01 Phase 3 trial. The trial demonstrated that Jazz Pharmaceuticals’ Ziihera, when used in combination with chemotherapy, showed significant improvements in progression-free survival and overall survival for patients with HER2-positive gastroesophageal adenocarcinoma. These results suggest that Ziihera could become a new standard of care, potentially replacing the current treatment, trastuzumab.
Additionally, the safety profile of Ziihera was consistent with existing data, with no new safety concerns emerging. Jazz Pharmaceuticals’ plans to submit a supplemental Biologics License Application in the first half of 2026 further underpin the positive outlook. The ongoing trials in other cancer types, such as biliary tract and breast cancer, could expand Ziihera’s indications and revenue potential, contributing to the Buy rating.
In another report released today, Needham also maintained a Buy rating on the stock with a $210.00 price target.